Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the first healthy volunteers (HV) have been dosed in the clinical First in Human (FIH) study. The first...
Read MoreEJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...
Read MoreAptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the first healthy volunteers have been screened for inclusion in the clinical First in Human (FIH) study with...
Read MoreAptahem can today announce that the Toronto team, in extended studies in addition to previously reported positive preliminary data, has concluded significant positive effects in a severe Corona virus induced Acute Lung Injury model with Apta-1 treatment. The preliminary...
Read MoreMikael Lindstam, CEO at Aptahem, was interviewed during the Biotechgate digital partnering conference. In the video he describes the development process with the company’s lead candidate Apta-1, from discovery, through manufacturing and preclinical studies up to clinical phase. The...
Read MoreEJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...
Read MoreAptahem’s nomination committee for the AGM next year has held a meeting. The nomination committee consists of three members represententing the three largest owners as of 30 September this year that wish to appoint a representative to the committee...
Read MoreAptahem has taken several steps forward in 2022. Recently, the biotech company passed a milestone with the start of the clinical phase I study with the sepsis candidate Apta-1. CEO Mikael Lindstam visited BioStock’s studio to present the company...
Read MoreAnalyst Group publicerade den 17 november 2022 en videointervju med VD Mikael Lindstam där han kommenterar den nyligen inledda kliniska Fas 1-studien och den förestående företrädesemissionen. Intervjun finns tillgänglig på Analyst Groups webbsida och på www.aptahem.com. För ytterligare information:...
Read MoreEJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...
Read More